Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H8N2O2S.ClH |
| Molecular Weight | 208.666 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NC1=CC=C(C=C1)S(N)(=O)=O
InChI
InChIKey=XZMIAZCXISFPEJ-UHFFFAOYSA-N
InChI=1S/C6H8N2O2S.ClH/c7-5-1-3-6(4-2-5)11(8,9)10;/h1-4H,7H2,(H2,8,9,10);1H
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.08 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/27010464 |
10 mg/kg bw single, oral dose: 10 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
SULFANILAMIDE plasma | Capra hircus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
81.3 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/27010464 |
10 mg/kg bw single, oral dose: 10 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
SULFANILAMIDE plasma | Capra hircus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.71 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/27010464 |
10 mg/kg bw single, oral dose: 10 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
SULFANILAMIDE plasma | Capra hircus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
15 % 1 times / day steady, topical Recommended Dose: 15 %, 1 times / day Route: topical Route: steady Dose: 15 %, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: bacterial infection (Candida albicans) Age Group: adult Sex: F Sources: |
Other AEs: Local reaction... Other AEs: Local reaction (0.2%) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Local reaction | 0.2% | 15 % 1 times / day steady, topical Recommended Dose: 15 %, 1 times / day Route: topical Route: steady Dose: 15 %, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: bacterial infection (Candida albicans) Age Group: adult Sex: F Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Repeat antibiotic prescriptions following treatment with sulfonamide or pivmecillinam. A survey of prescriptions among women aged 15-50 years in the county of Nordjylland]. | 2001 Dec 31 |
|
| Primary prevention with cotrimoxazole for HIV-1-infected adults: results of the pilot study in Dakar, Senegal. | 2001 Feb 1 |
|
| Development of an ELISA for sulfachlorpyridazine and investigation of matrix effects from different sample extraction procedures. | 2001 Jan |
|
| [Current approaches to treatment of secondary sulfonylamide drug resistance in Type II diabetes mellitus]. | 2001 Mar-Apr |
|
| Molecular epidemiology of cystic fibrosis-linked Burkholderia cepacia complex isolates from three national referral centres in Ireland. | 2002 |
|
| Antimicrobial use and antimicrobial resistance: a population perspective. | 2002 Apr |
|
| Sulphonamide residues in eggs following drug administration via the drinking water. | 2002 Apr |
|
| Pharmacokinetics of organic anions in rats with arterial calcinosis. | 2002 Jan-Feb |
|
| Release characteristics of pectin microspheres prepared by an emulsification technique. | 2002 Jul-Aug |
|
| The sorption and transport of a sulphonamide antibiotic in soil systems. | 2002 May 10 |
|
| Idiosyncratic NSAID drug induced oxidative stress. | 2002 Nov 10 |
|
| Sulphonamide resistant commensal Neisseria with alterations in the dihydropteroate synthase can be isolated from carriers not exposed to sulphonamides. | 2002 Nov 18 |
|
| The enhancement of the hyperglycemic effect of S-nitrosoglutathione and S-nitroso-N-acetylpenicillamine by vitamin C in an animal model. | 2002 Sep 13 |
|
| Design and synthesis of fluorescent beta-cyclodextrins for the enantioselective sensing of alpha-amino acids. | 2003 |
|
| Sulphonamide resistance gene sul3 found in Escherichia coli isolates from human sources. | 2003 Dec |
|
| [Adverse cutaneous reaction to celecoxib: 6 cases]. | 2003 May |
|
| Generation of group-specific antibodies against sulfonamides. | 2003 Sep 24 |
|
| 4-sulphamoylphenyl semicarbazones with anticonvulsant activity. | 2004 Aug |
|
| A new method for purification of carbonic anhydrase isozymes by affinity chromatography. | 2004 Feb |
|
| Glucose 6 phosphate dehydrogenase deficiency in adults. | 2004 Jul |
|
| Emerging issues in infective endocarditis. | 2004 Jun |
|
| Theoretical study of gas-phase acidity, pKa, lipophilicity, and solubility of some biologically active sulfonamides. | 2004 Oct 15 |
Sample Use Guides
One applicatorful (about 6g) intravaginally once or twice daily. Improvements in symptoms should
occur within a few days, but treatment should be continued for a period of 30 days.
Route of Administration:
Vaginal
Antimicrobial activity of sulfanilamide was tested with different bacterial and yeast strains. MIC values were 8 ug/ml for Listeria innocua, Escherishia coli and Pseudomonas aeruginosa; 16 ug/ml for Staphylococcus aureu and Candida albicans; 100 ug/ml for Botrytis cinerea and Fusarium oxysporum culmorum.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID50209889
Created by
admin on Fri Dec 15 15:26:16 GMT 2023 , Edited by admin on Fri Dec 15 15:26:16 GMT 2023
|
PRIMARY | |||
|
R2MR7LN8WP
Created by
admin on Fri Dec 15 15:26:16 GMT 2023 , Edited by admin on Fri Dec 15 15:26:16 GMT 2023
|
PRIMARY | |||
|
80197
Created by
admin on Fri Dec 15 15:26:16 GMT 2023 , Edited by admin on Fri Dec 15 15:26:16 GMT 2023
|
PRIMARY | |||
|
6101-31-1
Created by
admin on Fri Dec 15 15:26:16 GMT 2023 , Edited by admin on Fri Dec 15 15:26:16 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
